Veracyte Management

Management criteria checks 4/4

Veracyte's CEO is Marc Stapley, appointed in Jun 2021, has a tenure of 2.83 years. total yearly compensation is $4.94M, comprised of 12.7% salary and 87.3% bonuses, including company stock and options. directly owns 0.15% of the company’s shares, worth $2.21M. The average tenure of the management team and the board of directors is 2.2 years and 6.5 years respectively.

Key information

Marc Stapley

Chief executive officer

US$4.9m

Total compensation

CEO salary percentage	12.7%
CEO tenure	2.8yrs
CEO ownership	0.2%
Management average tenure	2.2yrs
Board average tenure	6.5yrs

Recent management updates

Recent updates

Lacklustre Performance Is Driving Veracyte, Inc.'s (NASDAQ:VCYT) Low P/S

Apr 18

A Look At The Intrinsic Value Of Veracyte, Inc. (NASDAQ:VCYT)

Mar 18

Veracyte Percepta Genomic Sequencing Classifier demonstrates accuracy in lung cancer risk

Jul 13

Veracyte: Not A Healthy Diagnosis

May 12

Valuing Veracyte Stock

Oct 03

CEO Compensation Analysis

How has Marc Stapley's remuneration changed compared to Veracyte's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	n/a	n/a	-US$74m
Sep 30 2023	n/a	n/a	-US$50m
Jun 30 2023	n/a	n/a	-US$29m
Mar 31 2023	n/a	n/a	-US$30m
Dec 31 2022	US$5m	US$625k	-US$37m
Sep 30 2022	n/a	n/a	-US$43m
Jun 30 2022	n/a	n/a	-US$49m
Mar 31 2022	n/a	n/a	-US$48m
Dec 31 2021	US$6m	US$350k	-US$76m

Compensation vs Market: Marc's total compensation ($USD4.94M) is about average for companies of similar size in the US market ($USD5.57M).

Compensation vs Earnings: Marc's compensation has been consistent with company performance over the past year.

CEO

Marc Stapley (53 yo)

2.8yrs

Tenure

US$4,935,422

Compensation

Mr. Marc A. Stapley serves as Chief Executive Officer at Veracyte, Inc. since June 1, 2021 and serves as its Director since June 08, 2021. He served as the Chief Executive Officer of Helix OpCo, LLC from A...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Marc Stapley	CEO & Director	2.8yrs	US$4.94m	0.15% $ 2.2m
Rebecca Chambers	Executive VP & CFO	2.8yrs	US$3.32m	0.045% $ 651.9k
Annie McGuire	Executive VP	2.2yrs	US$2.51m	0.084% $ 1.2m
Jonathan Wygant	VP & Chief Accounting Officer	2.2yrs	no data	0.011% $ 159.1k
Steven French	Senior VP & Chief Information Officer	2.3yrs	no data	no data
Phillip Febbo	Chief Scientific & Medical Officer	less than a year	no data	no data
Karen Possemato	Senior Vice President of Corporate Marketing	less than a year	no data	no data
Robert Brainin	Executive VP & Chief Business Officer	2.8yrs	no data	no data
John Leite	Chief Commercial Officer for CLIA Business	1.6yrs	no data	0.010% $ 151.6k
Corinne Danan	Senior Vice President	less than a year	no data	no data
Beverly Alley	VP & Corporate Controller	3.3yrs	US$1.29m	no data
Shayla Gorman	Director of Investor Relations	no data	no data	no data

2.2yrs

Average Tenure

52yo

Average Age

Experienced Management: VCYT's management team is considered experienced (2.2 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Marc Stapley	CEO & Director	2.8yrs	US$4.94m	0.15% $ 2.2m
Karin Eastham	Independent Director	11.3yrs	US$314.99k	0.031% $ 456.1k
Evan Jones	Independent Director	16.2yrs	US$314.99k	0.037% $ 543.1k
John Bishop	Lead Independent Director	9.3yrs	US$314.99k	0.031% $ 456.1k
Robert Epstein	Independent Chair	9.3yrs	US$307.49k	0.031% $ 456.1k
Jens Holstein	Independent Director	3.7yrs	US$318.37k	0.022% $ 325.4k
Edison Liu	Member of Scientific Advisory Board	no data	no data	no data
Muna Bhanji	Independent Director	3.1yrs	US$299.99k	0.020% $ 291.6k
Eliav Barr	Independent Director	1.7yrs	US$518.75k	no data

6.5yrs

Average Tenure

66yo

Average Age

Experienced Board: VCYT's board of directors are considered experienced (6.5 years average tenure).

Veracyte Management

Management criteria checks 4/4

Key information

Recent management updates

Independent Director notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Veracyte, Inc. Announces Retirement of John L. Bishop, A Member of the Board of Directors

Veracyte, Inc. Appoints Phillip G. Febbo as Chief Scientific Officer and Chief Medical Officer, Effective 2, 2023

Veracyte, Inc. Announces Resignation of Tina S. Nova as General Manager, Urological Cancers Effective September 4, 2023

Independent Director notifies of intention to sell stock

Recent updates

Independent Director notifies of intention to sell stock

Independent Director notifies of intention to sell stock

New minor risk - Shareholder dilution

New minor risk - Profitability

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Veracyte, Inc. Provides Earnings Guidance for the Full Year 2024

Veracyte, Inc. Announces Retirement of John L. Bishop, A Member of the Board of Directors

Veracyte, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Veracyte, Inc. (NasdaqGM:VCYT) completed the acquisition of C2i Genomics, Inc.

Veracyte, Inc. (NasdaqGM:VCYT) has reached a definitive agreement to acquire C2i Genomics, Inc. for $95 million.

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Revenue and earnings growth

Veracyte, Inc. Reports Consolidated Impairment Charges for the Quarter Ended September 30, 2023

Veracyte, Inc. Raises Revenue Guidance for the Full Year 2023

Veracyte, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Veracyte, Inc. Announces New Data from A Large, Randomized Phase 3 Trial Reinforce the Value of the Decipher Prostate Genomic Classifier in Helping Physicians Make More Informed Treatment Decisions for Their Patients with Prostate Cancer

Veracyte, Inc. Announces New Data Presented At the 2023 American Thyroid Association Annual Meeting Demonstrate That Veracyte's Afirma-Based Testing Can Uncover Key Molecular Hallmarks of Thyroid Cancer

Veracyte, Inc. Appoints Phillip G. Febbo as Chief Scientific Officer and Chief Medical Officer, Effective 2, 2023

Veracyte, Inc. Announces Findings Published in JCO Precision Oncology Suggest Potential of Decipher GRID-Derived Gene Signatures to Predict Treatment Response in Recurrent Prostate Cancer

Consensus estimates of losses per share improve by 11%

Veracyte, Inc. Announces Resignation of Tina S. Nova as General Manager, Urological Cancers Effective September 4, 2023

Veracyte, Inc. Revises Revenue Guidance for the Full Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Veracyte, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Veracyte, Inc. Announces New Data Suggest Veracyte's Afirma Molecular Testing Capabilities Can Help Advance Scientific Understanding of Thyroid Nodules and Cancer

Independent Director notifies of intention to sell stock

Veracyte Announces That New Data Show Use of the Prosigna Test Significantly Changed Treatment Decisions for Patients with Early-Stage Breast Cancer

Veracyte, Inc. Raises Earnings Guidance for the Full-Year 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Lacklustre Performance Is Driving Veracyte, Inc.'s (NASDAQ:VCYT) Low P/S

Co-Founder & Executive Chairwoman notifies of intention to sell stock

Co-Founder & Executive Chairwoman notifies of intention to sell stock

A Look At The Intrinsic Value Of Veracyte, Inc. (NASDAQ:VCYT)

Independent Director notifies of intention to sell stock

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Veracyte, Inc. Announces New Data To Be Presented at 2023 ASCO GU Suggest Decipher GRID-Derived Gene Expression Signature Can Help Personalize Prostate Cancer Treatment

Veracyte, Inc. to Report Q4, 2022 Results on Feb 22, 2023

Co-Founder & Executive Chairwoman exercised options and sold US$682k worth of stock

Veracyte, Inc. Announces Resignation of Giulia C. Kennedy as Global Chief Scientific Officer and Chief Medical Officer

Co-Founder & Executive Chairwoman exercised options and sold US$1.4m worth of stock

Independent Director recently sold US$181k worth of stock

Consensus estimates of losses per share improve by 28%

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Veracyte, Inc. Raises Revenue Guidance for the Year 2022

Veracyte, Inc. Announces New Data Suggest Decipher GRID-Derived Genomic Signature Can Help Identify Men with Prostate Cancer Who Should Receive High-Dose Radiotherapy

Veracyte, Inc. Announces Data That Provide New Insights into Thyroid Tumor Behavior

New Data Presented At American College of Chest Physicians 2022 Reinforce Clinical Value of Veracyte’s Genomic Tests in Interstitial Lung Disease and Lung Cancer

Co-Founder & Executive Chairwoman exercised options to buy US$188k worth of stock.

Veracyte, Inc. to Report Q3, 2022 Results on Nov 02, 2022

Veracyte, Inc. Publishes New Data in JNCI Demonstrate its Decipher Prostate Genomic Classifier May Improve Identification of Aggressive Prostate Cancer in African American Men

Veracyte, Inc. Names John Leite as Senior Vice President and General Manager of Pulmonology & Market Access

Veracyte, Inc. Announces That New Data from a Phase 3 Trial of the Multi-Center, Multi-National, Randomized Stampede Platform Protocol

Veracyte, Inc. Announces New Data in Nature Medicine Suggest Pre-Treatment Tumor Microenvironment Can Impact Response for Car T-Cell Therapy in Patients with Large B-Cell Lymphoma

Veracyte, Inc. Appoints Eliav Barr to Its Board of Directors

Co-Founder & Executive Chairwoman recently sold US$3.4m worth of stock

Consensus estimates of losses per share improve by 10%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Veracyte, Inc. Revises Revenue Guidance for the Year 2022

Consensus forecasts updated

Veracyte, Inc. Announces New Clinical Validation Data for RNA Sequencing-Based Afirma Medullary Thyroid Cancer Classifier Published in Thyroid

Veracyte, Inc. to Report Q2, 2022 Results on Aug 02, 2022

Veracyte, Inc. Announces New Data Published in PLOS ONE Validate the Clinical Performance of Veracyte’s Percepta Genomic Sequencing Classifier in Lung Cancer Diagnosis

Veracyte Percepta Genomic Sequencing Classifier demonstrates accuracy in lung cancer risk

Veracyte, Inc. Shows Strong Performance of Veracyte’s Afirma GSC in Real-World Clinical Practice

CEO & Director recently bought US$980k worth of stock

Veracyte, Inc. Announces the Publication of Data Reinforcing the Clinical Utility of the Decipher Prostate Genomic Classifier

Veracyte, Inc. Announces that New Data Show Immunoscore IC Assay May Predict Patients Likely to Benefit from Addition of Immunotherapy to Standard First-Line Therapy for Metastatic Colorectal Cancer

Veracyte, Inc. Announces New Data to be Presented at ASCO 2022 Showing Immunoscore IC Assay’s Ability to Identify Patients with NSCLC Who May Benefit from Immune Checkpoint Inhibitors

Veracyte, Inc. Announces New Data Reinforcing Percepta Nasal Swab Test’s Clinical Performance and Utility in Lung Cancer Risk Assessment